Alivus Life Sciences Ltd
Microcap 250
₹1,386.80
-0.24%
Delayed · cached 15 min
Fair value analysis
ALIVUS
Alivus Life Sciences Ltd
₹1,390.20
Close used for this calculation
₹7,023.86Fair value
The valuation models disagreed widely for this stock, so this figure is an unweighted average of the middle of their range. Treat it as indicative only.
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
31/100
Quality radar
Consensus fair value
₹7,023.86
Below FV▲ +405.2% against the close used
Model range ₹509.51 – ₹12,807.02
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹509.51Fair value₹7,023.86Bull₹12,807.02
FairClose
52-week traded range
52W low ₹860.0552W high ₹1,443.70
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Alivus Life Sciences Ltd closed at ₹1,390.20, 80.2% below the consensus fair value of ₹7,023.86 drawn from 5 valuation models.
Financial DNA score 31/100 — Weak. P/E of 48.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹6,723.70
+383.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
₹12,807.02
+821.2%
EPS × 35.7x (sector P/E)
EPS=358.74, Sector P/E=35.7x
EV/EBITDA
₹509.51
-63.4%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=6.24B
Reverse DCF
₹1,390.20
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -10% | Historical: 0%
Margin of Safety
₹7,324.02
+426.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=9765.36, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.